AT7519, A Potent CDK Inhibitor, is Active in Leukaemia Models and Primary CLL Patient Samples MS Squires1, RE Feltell1, V Lock1, D Smith1, EJ Lewis1, J Higgins1, M Yule1, NT Thompson1, L Cooke2, K Della Croce2, W Qi2, JF - Retinoblastoma - Document - PDFSEARCH.IO

First Page	Meta Content
	AT7519, A Potent CDK Inhibitor, is Active in Leukaemia Models and Primary CLL Patient Samples MS Squires1, RE Feltell1, V Lock1, D Smith1, EJ Lewis1, J Higgins1, M Yule1, NT Thompson1, L Cooke2, K Della Croce2, W Qi2, JF Add to Reading List Open Document File Size: 276,27 KB Share Result on Facebook City Atlanta / Cambridge / Tuscon / / Company Therapeutics Ltd. / Astex Therapeutics Limited. / / Country United Kingdom / / Currency pence / / Event FDA Phase / / MedicalCondition B-Cell lymphoproliferative disorders / HL60 promyelocytic leukaemia cells / disease / leukaemia cells / MS / tumour / leukaemia cell lines / both leukaemia cell lines / / Organization 2Arizona Cancer Center / American Society for Hematology / / Position consultant / / Product IC50 / / ProvinceOrState Aurora / Arizona / / Technology apoptosis / / SocialTag Proteins Apoptosis Cyclin CDK inhibitor Survivin Retinoblastoma protein B-cell chronic lymphocytic leukemia Biology Cell biology Cell cycle

AT7519, A Potent CDK Inhibitor, is Active in Leukaemia Models and Primary CLL Patient Samples MS Squires1, RE Feltell1, V Lock1, D Smith1, EJ Lewis1, J Higgins1, M Yule1, NT Thompson1, L Cooke2, K Della Croce2, W Qi2, JFAdd to Reading List